<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512135</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 60201-0609/1</org_study_id>
    <nct_id>NCT00512135</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IncobotulinumtoxinA (Xeomin) in the Treatment of Glabellar Frown Lines</brief_title>
  <official_title>A Prospective, Open-label, Multicenter, Repeat-dose Trial to Investigate the Safety and Efficacy of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective was to investigate the safety and efficacy of incobotulinumtoxinA
      (Xeomin) during repeat dose treatment of glabellar frown lines. 801 subjects with moderate to
      severe glabellar frown lines at maximum frown who completed participation in one of the
      studies in this program, i.e., MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ
      60201-0741/1 were eligible to participate in this repeat-dose study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, multicenter, open-label, non-control group design Phase 3 clinical
      study. Approximately 880 subjects who were to complete former studies in this program (370
      subjects from studies MRZ 60201-0520/1 (8) and MRZ 60201-0527/1 (8) as well as approximately
      510 subjects from studies MRZ 60201-0724/1 (10) and MRZ 60201-0741/1) (11) were expected to
      enroll in this study in 26 centers in the United States, Canada and Germany. Subjects with
      moderate to severe glabellar frown lines at maximum frown who completed participation in one
      of these four &quot;feeder&quot; studies in the frown line program were eligible to participate in this
      repeated dose study.

      Each subject received a dose of 20 units incobotulinumtoxinA (Xeomin) for i.m. injection on
      Visit 1 (Day 0 of Cycle 1). Re-injections with 20 U NT 201 could be performed on Day 0 of a
      subsequent cycle for up to 8 cycles (one cycle ≥ 85 days). Intervals between treatments were
      at least three months or 12 weeks, i.e., ≥ 85 days. For a new treatment cycle to start, the
      subject had to request a re-injection. The investigator then had to assess if the glabellar
      frown lines had relapsed to 'moderate' or 'severe'. In this case, a new injection could be
      administered. The treatment duration per subject was 24 months and up to eight cycles for
      subjects enrolled from studies MRZ 60201-0520/1 and MRZ 60201-0527/1 and 6 months and up to
      two cycles for subjects enrolled from studies MRZ 60201-0724/1 and MRZ 60201-0741/1,
      respectively. Subjects enrolled from studies MRZ 60201-0520/1 and MRZ 60201-0527/1
      participated at least one year in the study whereas subjects enrolled from studies MRZ
      60201-0724/1 and MRZ 60201-0741/1 participated for six months and up to two cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Safety endpoints - Investigator's assessment - Patient's assessment</measure>
    <time_frame>Assessment at days 30 and &gt;84</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">796</enrollment>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) (20 units)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (Xeomin) (20 units)</intervention_name>
    <description>Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.</description>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) (20 units)</arm_group_label>
    <other_name>IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins (20 units)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with 'moderate' or 'severe' glabellar frown lines at maximum frown at the
        beginning of each treatment cycle (as assessed by the investigator according to FWS) ,
        stable medical condition; Completion of one former study in the Merz NT 201 glabellar
        program

        Exclusion:

        Patients with preexisting neuromuscular diseases (e.g. myasthenia gravis, Lambert-Eaton
        syndrome) putting the patient at risk, History of Facial Nerve Palsy, Previous treatment
        with Botulinum Toxin in the glabellar area during the last 12 months, Previous treatment
        with biodegradable fillers or other procedures (e.g. chemical peeling, photo rejuvenation)
        in the glabellar area during the last 12 months, Previous insertion of permanent material
        in the glabellar area; Planned treatment with Botulinum toxin of any serotype in any body
        region during the study period, Any other planned facial aesthetic procedure in the
        glabellar area during the trial period; Any surgery in the glabellar area including
        surgical removal of the corrugator, procerus or depressor supercili muscles or a
        combination of these or scars in the glabellar area, Inability to substantially lessen
        glabellar frown lines even by physically spreading apart, Marked facial asymmetry or ptosis
        of eyelid and/or eyebrow; Any infection in the area of the injection sites.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berthold Rzany, Prof. Dr. med Sc.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Evidence Based Medicine dEBM, Department of Dermatology, Venerology and Allergology , Charité - University Medicine, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Corcoran Flynn, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care Centre</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>About Skin Dermatology</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Cosmetic Enhancement</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandt</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Dermatology Research Institute</name>
      <address>
        <city>Lincolnshire</city>
        <state>Illinois</state>
        <zip>60069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp;Skin Surgery Center of Indiana</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coleman</name>
      <address>
        <city>Metarie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Physisians of Chestnut Hill</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlessinger</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Dermatology P.C.</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narins</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flynn Consulting PLLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carruthers Dermatology Centre Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solish</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin - Klinik für Dermatologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenparkklinik</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann-Wolfgang-Goethe- Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Saarland</name>
      <address>
        <city>Homburg / Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Michael Sebastian</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hans-Ulrich Voigt</name>
      <address>
        <city>München</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Thomas Dirschka</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rzany B, Flynn TC, Schlöbe A, Heinz M, Harrington L. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines. Dermatol Surg. 2013 Jan;39(1 Pt 1):95-103. doi: 10.1111/dsu.12008. Epub 2012 Nov 27.</citation>
    <PMID>23190342</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2007</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

